Transmedics Group Stock Price, News & Analysis

TransMedics Group (Nasdaq: TMDX) will present at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:50 a.m. EST. The executive team's presentation aims to highlight advancements in organ transplant therapy, particularly for patients experiencing end-stage lung, heart, and liver failure. TransMedics is a leader in portable warm perfusion technology, focusing on improving organ quality and viability assessment prior to transplantation.

Investors can access a live and archived webcast of the presentation on the TransMedics website.

TransMedics Group, Inc. (Nasdaq: TMDX) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. A conference call to discuss the results will take place at 4:30 p.m. ET. The company specializes in portable extracorporeal warm perfusion for organ transplants, aiming to enhance organ availability for patients with end-stage conditions. Interested investors can access the call via phone or through a live webcast available on their website.

TransMedics Group, Inc. (Nasdaq: TMDX) announced on January 5, 2022, the publication of results from the OCS™ Liver PROTECT Trial in JAMA Surgery. The trial, which involved 300 participants, demonstrated significant improvements in short-term and mid-term clinical outcomes for liver transplants using the OCS™ Liver System. Key findings include a 41% reduction in early allograft dysfunction (EAD) and a higher utilization of livers from cardiac death donors. CEO Waleed Hassanein emphasized that these results could expand the donor pool and improve patient outcomes.

TransMedics Group, a leader in organ transplant technology, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. EST. The virtual event aims to showcase the company's advancements in portable warm perfusion and assessment of donor organs for transplantation. Founded to enhance organ availability and quality, TransMedics is dedicated to addressing the needs of patients with end-stage heart, lung, and liver failure. Interested parties can access the presentation live and archived on the TransMedics website.

TransMedics Group, Inc. (TMDX) announced the grant of non-qualified stock options for 240,500 shares of its common stock to eleven employees on November 5, 2021. The options, aimed at incentivizing new hires, were approved by the Compensation Committee and adhere to Nasdaq Listing Rule 5635(c)(4). Each option has a ten-year term with an exercise price of $31.49, the stock's closing price on the grant date. Vesting occurs at 25% after one year and monthly thereafter over three years, contingent on continued employment.

TransMedics Group, Inc. (TMDX) reported Q3 2021 net revenue of $5.4 million, a 24% decrease from Q3 2020. This decline is attributed to the end of revenue from clinical trials for OCS Heart and OCS Liver before FDA approvals. Notable achievements include FDA 510(k) clearance for OCS Lung and PMA for OCS Heart and Liver systems in July and September 2021, respectively. Operating expenses rose to $15.5 million, leading to a net loss of $13.0 million. The company anticipates full-year revenue between $27.6 million and $28.6 million, indicating 8% to 12% growth compared to 2020.

TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplantation technology, will host one-on-one meetings at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on November 18, 2021. The company is dedicated to improving organ transplant therapy for patients with end-stage lung, heart, and liver failure. TransMedics specializes in portable extracorporeal warm perfusion and assessment of donor organs, aiming to enhance organ quality and increase the utilization of donor organs.

On November 4, 2021, TransMedics Group announced positive topline results from its OCS DCD Heart Trial, the first randomized trial comparing outcomes of hearts from DCD donors using the OCS Heart System to those from DBD donors. The trial achieved a 95% patient survival rate at 6 months for the OCS DCD arm, outperforming the 89% for DBD controls. A total of 90 out of 101 DCD donor hearts were successfully transplanted, yielding an impressive 89% utilization rate. These results will be submitted to the FDA for further OCS DCD heart indication approval.

TransMedics Group (TMDX) will announce its third-quarter financial results on November 9, 2021, after market close. A conference call with management is scheduled for 4:30 p.m. ET. The company specializes in organ transplant technology, focusing on enhancing organ quality and viability for patients with end-stage organ failure. Investors can listen to the call by dialing specific numbers provided or accessing the webcast on TransMedics’ website.